RT Journal Article
SR Electronic
T1 Serum Markers Predict Brain Death Due to Trauma and Hypoxia Within 32 hours of Injury
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.13.21251369
DO 10.1101/2021.02.13.21251369
A1 Daniel Rafter
A1 Brett Sterk
A1 Zhuliu Li
A1 Tory Schaaf
A1 Rui Kuang
A1 Michael Koller
A1 Uzma Samadani
YR 2021
UL http://medrxiv.org/content/early/2021/02/18/2021.02.13.21251369.abstract
AB Objective Brain death is a controversial construct because proving irreversible cessation of neurologic function is difficult, and ascertaining the timepoint at which irreversibility has occurred is not currently possible. The ability to predict which traumatic (TBI) and hypoxic brain injuries will progress to brain death is also limited. We investigated how accurately neurologic serum markers can predict brain death and differentiate its etiology.Methods This prospective observational study enrolled brain injury subjects presenting to a trauma center within 32 hours of injury. Levels of glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and S100 Calcium-Binding Protein B (S100B) were compared. Clinically brain dead (BD) subjects were further subdivided into high velocity trauma with presumed diffuse axonal injury (DAI), cardiopulmonary/respiratory arrest (CA/RA), and found down (FD).Results The prognostic value of various biomarker combinations in identifying subjects progressing to brain death was assessed using machine learning. Prediction accuracy for GFAP, UCH-L1, and S100B in combination to predict brain death from among all other cohorts yielded an area under the curve (AUC) of 0.98 versus all other brain injury subjects. This model was also able to distinguish CA/RA BD from combined non-trauma controls and DAI BD with an AUC of 0.99.Conclusion Serum concentrations of GFAP, UCH-L1, and S100B measured within 32 hours of traumatic and hypoxic brain injury have utility in prognosticating brain death by mechanism of injury as either hypoxic (CA/RA) or traumatic/unknown (DAI and FD).Competing Interest StatementDr. Uzma Samadani reports receiving lecture fees from Abbott; the American Association of Neuroscience Nurses; Cottage Health; Google Inc.; Integra Corp; Medtronic Corp; National Neurotrauma Society; Minnesota, Texas, Louisiana, and Wisconsin Coaches Associations; and the National Football League and USA Football. She also reports receiving grant support from the State of Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program administered by the Minnesota Office of Higher Education, Veterans Administration, Abbott Laboratories, Medtronic, and Integra. Finally, she reports serving as an unaffiliated neurotrauma consultant to the National Football League for five games during each of the 2015 to 2018 football seasons.Funding StatementThis study was funded by Abbott Labs and the Minnesota State Office of Higher Education Project Number 176016. Neither played a role in generation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hennepin Healthcare Institutional Review Board approval (HSR #15-4079) was obtained for prospective enrollment of patients who presented to the emergency department of a level-1 trauma center between May 2016 and April 2017.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request.